Stoke Therapeutics Inc
NASDAQ:STOK
Intrinsic Value
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. [ Read More ]
The intrinsic value of one STOK stock under the Base Case scenario is 7.07 USD. Compared to the current market price of 11.91 USD, Stoke Therapeutics Inc is Overvalued by 41%.
Valuation Backtest
Stoke Therapeutics Inc
Run backtest to discover the historical profit from buying and selling STOK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Stoke Therapeutics Inc
Current Assets | 193.3m |
Cash & Short-Term Investments | 178.6m |
Receivables | 11k |
Other Current Assets | 14.7m |
Non-Current Assets | 11.9m |
PP&E | 11.3m |
Other Non-Current Assets | 569k |
Current Liabilities | 35.6m |
Accounts Payable | 2.1m |
Accrued Liabilities | 11.6m |
Other Current Liabilities | 21.9m |
Non-Current Liabilities | 29.3m |
Other Non-Current Liabilities | 29.3m |
Earnings Waterfall
Stoke Therapeutics Inc
Revenue
|
7.8m
USD
|
Operating Expenses
|
-126.3m
USD
|
Operating Income
|
-118.4m
USD
|
Other Expenses
|
9.9m
USD
|
Net Income
|
-108.5m
USD
|
Free Cash Flow Analysis
Stoke Therapeutics Inc
STOK Profitability Score
Profitability Due Diligence
Stoke Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Stoke Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
STOK Solvency Score
Solvency Due Diligence
Stoke Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Stoke Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
STOK Price Targets Summary
Stoke Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for STOK is 23.97 USD with a low forecast of 17.17 USD and a high forecast of 36.75 USD.
Ownership
STOK Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
STOK Price
Stoke Therapeutics Inc
Average Annual Return | 0.43% |
Standard Deviation of Annual Returns | 84.52% |
Max Drawdown | -95% |
Market Capitalization | 620.7m USD |
Shares Outstanding | 52 117 500 |
Percentage of Shares Shorted | 24% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2019-06-19. The company focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. The company is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. The company focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. The company utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.
Contact
IPO
Employees
Officers
The intrinsic value of one STOK stock under the Base Case scenario is 7.07 USD.
Compared to the current market price of 11.91 USD, Stoke Therapeutics Inc is Overvalued by 41%.